COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    LY3405105
Previous Study | Return to List | Next Study

A Study of LY3405105 in Participants With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03770494
Recruitment Status : Suspended (Enrollment on hold due to COVID-19 pandemic.)
First Posted : December 10, 2018
Last Update Posted : May 5, 2020
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts (A and B). Participants will only enroll in one part.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: LY3405105 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 215 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Actual Study Start Date : January 31, 2019
Estimated Primary Completion Date : May 5, 2022
Estimated Study Completion Date : May 5, 2022

Arm Intervention/treatment
Experimental: LY3405105
LY3405105 administered orally.
Drug: LY3405105
Administered orally.

Primary Outcome Measures :
  1. Number of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: Baseline through Cycle 1 (28 Day Cycle) ]
    Number of participants with DLTs

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3405105 [ Time Frame: Predose Lead in Day 1 through Predose Cycle 2 Day 1 (28 Day Cycles) ]
    PK: AUC of LY3405105

  2. Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR) [ Time Frame: Baseline through Measured Progressive Disease (Estimated up to 6 Months) ]
    ORR: Percentage of participants with a CR or PR

  3. Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR [ Time Frame: Baseline through Measured Progressive Disease (Estimated up to 6 Months) ]
    DCR: Percentage of participants who exhibit SD, CR or PR

  4. Duration of Response (DOR) [ Time Frame: Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months) ]

  5. Time to Response (TTR) [ Time Frame: Baseline to Date of CR or PR (Estimated up to 6 Months) ]

  6. Progression Free Survival (PFS) [ Time Frame: Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months) ]

  7. Overall Survival (OS) [ Time Frame: Baseline to Date of Death from Any Cause (Estimated up to 12 Months) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have histological or cytological evidence of a diagnosis of a solid tumor cancer that is advanced and/or metastatic
  • Have available archived tissue for exploratory biomarker analysis
  • Have adequate organ function
  • Have discontinued all previous treatments for cancer and recovered from their side effects
  • Are able to swallow capsules/tablets

Exclusion Criteria:

  • Have symptomatic central nervous system (CNS) malignancy or metastasis
  • Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C
  • Have congestive heart failure
  • Are breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03770494

Show Show 20 study locations
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT03770494    
Other Study ID Numbers: 17125
J1F-MC-JZFA ( Other Identifier: Eli Lilly and Company )
2018-002668-23 ( EudraCT Number )
First Posted: December 10, 2018    Key Record Dates
Last Update Posted: May 5, 2020
Last Verified: May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No